Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_02345 |
| Species: | Homo sapiens |
| Position : | chr6:12826550-12826620 |
| Year: | 2015 |
| Title: | Myocardial Infarction-Associated SNP at 6p24 Interferes With MEF2 Binding and Associates With PHACTR1 Expression Levels in Human Coronary Arteries. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | coronary artery disease |
| PMID: | 25838425 |
| Tissue: | aorta |
| Tissue Ontology ID: | UBERON:0000947 |
| Cell Source: | hESC-derived endothelial cells |
| Cell Type: | endothelial cell |
| Cell Ontology ID: | CL:0000115 |
| Experiment Type: | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| High Throughput Method: | eQTL analysis; GWAS |
| Low Throughput Method: | EMSA, CRISPR knockout, RT-RT-qPCR; CRISPR-Cas9 endogenous deletion/editing |
| Target gene : | PHACTR1 |
| TF name : | MEF2A |
| Regulatory State : | Repressed |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MEF2A | CDO in myogenesis | reactome | 29 |
| MEF2A | ERK/MAPK targets | reactome | 17 |
| MEF2A | Signaling mediated by p38-alpha and p38-beta | pid | 35 |
| MEF2A | TGF_beta_Receptor | netpath | 220 |
| MEF2A | Hs_p38_MAPK_Signaling_Pathway_WP400_72084 | wikipathways | 28 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_02301 | chr6:12826550-12826620 | coronary artery | endothelial cell | myocardial infarction |